Ethopropazine and benztropine in neuroleptic-induced parkinsonism.

In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients. Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug. However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients. This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.
AuthorsG Chouinard, L Annable, A Ross-Chouinard, M L Kropsky
JournalThe Journal of clinical psychiatry (J Clin Psychiatry) Vol. 40 Issue 3 Pg. 147-52 (Mar 1979) ISSN: 0160-6689 [Print] United States
PMID33969 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Phenothiazines
  • Tropanes
  • Benztropine
  • Procyclidine
  • Fluphenazine
  • Adult
  • Benztropine (adverse effects, therapeutic use)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Dyskinesia, Drug-Induced (drug therapy)
  • Female
  • Fluphenazine (adverse effects, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease, Secondary (chemically induced, drug therapy)
  • Phenothiazines (adverse effects, therapeutic use)
  • Procyclidine (therapeutic use)
  • Schizophrenia (drug therapy)
  • Tropanes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: